135 related articles for article (PubMed ID: 32014943)
1. Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1.
Pezzuto A; Cappuzzo F; D'Arcangelo M; Ciccozzi M; Navarini L; Guerrini S; Ricci A; D'Ascanio M; Carico E
Anticancer Res; 2020 Feb; 40(2):983-990. PubMed ID: 32014943
[TBL] [Abstract][Full Text] [Related]
2. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
[TBL] [Abstract][Full Text] [Related]
6. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients.
Su CY; Chang YC; Chan YC; Lin TC; Huang MS; Yang CJ; Hsiao M
Eur J Surg Oncol; 2014 Sep; 40(9):1143-50. PubMed ID: 24969958
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
Vallonthaiel AG; Malik PS; Singh V; Kumar V; Kumar S; Sharma MC; Mathur S; Arava S; Guleria R; Jain D
Ann Diagn Pathol; 2017 Dec; 31():56-61. PubMed ID: 29146060
[TBL] [Abstract][Full Text] [Related]
8. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
Sun JM; Zhou W; Choi YL; Choi SJ; Kim SE; Wang Z; Dolled-Filhart M; Emancipator K; Wu D; Weiner R; Frisman D; Kim HK; Choi YS; Shim YM; Kim J
J Thorac Oncol; 2016 Jul; 11(7):1003-11. PubMed ID: 27103510
[TBL] [Abstract][Full Text] [Related]
12. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
13. Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer.
Grizzi F; Castello A; Qehajaj D; Toschi L; Rossi S; Pistillo D; Paleari V; Veronesi G; Novellis P; Monterisi S; Mineri R; Rahal D; Lopci E
Cancer Immunol Immunother; 2019 Sep; 68(9):1537-1545. PubMed ID: 31482306
[TBL] [Abstract][Full Text] [Related]
14. New P16 Expression Criteria Predict Lymph Node Metastasis in Patients With Non-small Cell Lung Cancer.
An HJ; Koh HM; Song DH
In Vivo; 2019; 33(6):1885-1892. PubMed ID: 31662516
[TBL] [Abstract][Full Text] [Related]
15. Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma.
Ağaçkıran Y; Aksu F; Akyürek N; Ercan C; Demiröz M; Aksu K
Asia Pac J Clin Oncol; 2021 Jun; 17(3):280-288. PubMed ID: 32929886
[TBL] [Abstract][Full Text] [Related]
16. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
17. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer.
Cheng YL; Lee SC; Harn HJ; Chen CJ; Chang YC; Chen JC; Yu CP
Eur J Cardiothorac Surg; 2003 Feb; 23(2):221-8. PubMed ID: 12559346
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.
Zhao Y; Shi F; Zhou Q; Li Y; Wu J; Wang R; Song Q
Medicine (Baltimore); 2020 Nov; 99(45):e23172. PubMed ID: 33158004
[TBL] [Abstract][Full Text] [Related]
19. SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma.
Glatzel-Plucinska N; Piotrowska A; Grzegrzolka J; Olbromski M; Rzechonek A; Dziegiel P; Podhorska-Okolow M
Anticancer Res; 2018 Feb; 38(2):723-736. PubMed ID: 29374696
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
